Atezolizumab w or w/o Bevacizumab in Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

I'm Interested!

Please call
1-800-641-2422

GENE 1224 (ML44719) A Phase II, Open-Label, Multi-Cohort, Multi-Center Study in Patients with un-resectable hepatocellular carcinoma and child-pugh B7 and B8 cirrhosis. GENE 1224 (ML44719)

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Pancreas

Study Purpose

The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.

Principal Investigator
Amit Mahipal MD

Department/Division
Cancer (Digestive System)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: Pro00079207
StudyID: GENE1224
ClinicalTrials.gov: NCT06096779

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422